AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04813705
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients with stage II will receive concurrent cisplatin during Intensity modulated radiotherapy (IMRT), and stage III-IVA patients will receive platinum based induction chemotherapy every 21 days for at least two cycles followed by concurrent cisplatin during IMRT.
Trial: NCT05702424
Drug: IGM-7354
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGM-7354 is a PD-L1-targeted cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects
Trial: NCT05290194
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is treated for patients 3-6 weeks after radiotherapy, which combines with PD-1 inhibitor as the maintenance regimen in the trial.
Trial: NCT05843188
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Folic acid derivative
Trial: NCT05843188
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antineoplastic agent
Trial: NCT05130814
Drug: zinc cream or hyaluronic acid sodium salt + metallic silver
RxNorm normalized name: formic acid, sodium salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied to prevent and/or treat the skin maceration of the surrounding area
Trial: NCT06543303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05835986
Drug: RO7507062
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7507062 solution for injection will be administered SC as specified in each treatment arm.
Trial: NCT06561061
Drug: zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dispersible (20 mg) tablet
Trial: NCT06561061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible tablet
Trial: NCT04723147
Drug: Carbidopa Levodopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive L-DOPA at doses ranging from 150 to 450 mg administered at a ratio of 1 mg carbidopa for every 4 mg L-DOPA. Starting dose is 150 mg/day with dose escalation 150 mg/day per week to a final dose of 450 mg/day
Trial: NCT04723147
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo is a sugar pill that has no therapeutic effect and will be administered orally. Participants will receive 1 placebo tablet matching the Carbidopa Levodopa tablet.
Trial: NCT05119569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally.
Trial: NCT04753437
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin tablets.
Trial: NCT05242042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching JT001 administered orally in tablet form every 12 hours for 5 days (10 doses total)
Trial: NCT05258773
Drug: SENS-401 (R-Azasetron Besylate)
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive SENS-401 ((R)-azasetron besylate) for 7 days B.I.D. before cochlear implant surgery and during 6 weeks after the surgery.
Trial: NCT05641870
Drug: Chemoradiation treatment regimen and maintenance (if amenable)
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated with standard chemotherapy (following the clinical practice at each institution). Radiotherapy will be delivered concurrently when feasible with a total dose of 60-66 Gy. In selected cases, due to frailty of the patient or impaired pulmonary function, radiotherapy will be delivered sequentially. In tumors with positive PD-L1 expression, a year of durvalumab 10 mg/m2 every 2 weeks will be administered if there are no contraindications.
Trial: NCT05699005
Drug: Packed Red Blood Cells (PRBCs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will recieve PRBCs transfusion only in case of ScVO2 level\<65% after assessment of patient for optimisation of SaO2 targeting 100%, volume status, ECMO flow (increase to 20% in relevant), pain, anxiety and fever (body temperature \>38°3).~In both groups transfusion may be performed in case massive bleeding according to local protocols, STEMI, Hyperlactatemia \>4 that can be related to oxygen demand and supply DO2/VO2 ratio impairement, in all groups, transfusion should be performed in case of hemolobin level \<7g/dL or worsening of neurological condition (Increase in Neurological SOFA component of 1 and more) related to DO2/VO2 impairement.
Trial: NCT06340048
Drug: HiCM-188 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes (HiCM-188) during coronary artery bypass grafting surgery
Trial: NCT05418673
Drug: BIIB122
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT04762953
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Leucovorin
Trial: NCT04762953
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV 5-FU
Trial: NCT06299111
Drug: REGN9933
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) single dose administered
Trial: NCT06299111
Drug: REGN7508
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV single dose administered
Trial: NCT06299111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV single dose administered
Trial: NCT04777357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT04704505
Drug: Bipolar Androgen Therapy (BAT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All Patients will receiveTestosterone Cypionate 400mg IM every 28 days, until progression or unacceptable toxicity.
Trial: NCT04542603
Drug: [11C]PiB and 18F-labeled DPA-714 PET scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One PET with \[11C\]PiB and One PET with \[18F\]DPA-714 before chemotherapy treatment begins. One more PET with \[18F\]DPA-714 after completion of 3-6 cycles of chemotherapy.
Trial: NCT06052163
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bumetanide is an FDA approved loop diuretic that has been used for more than three decades to treat edema, congestive heart failure, and hypertension across the life span. It has a well-known side effect profile. Most importantly it can cause dehydration and electrolyte imbalance especially at higher doses. This medication is given to individuals at the similar age group as Alzheimer's disease patients and Alzheimer's disease or cognitive impairment do not preclude its use in patients who need it for its FDA indications. At low doses and when titrated carefully, the medication is well tolerated. However, it has not been studied specifically in Alzheimer's disease patients.
Trial: NCT06052163
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo has no active properties and is taken orally.
Trial: NCT05251181
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
Trial: NCT05761574
Drug: Acetaminophen/Naproxen Sodium Fixed Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
Trial: NCT05761574
Drug: Naproxen Sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen Sodium will be administered orally.
Trial: NCT05761574
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen will be administered orally.
Trial: NCT05761574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally.
Trial: NCT05060705
Drug: Efesovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapy of COVID19 with Efesovir oral solution in dose 0.125 ml / kg two times per day. Duration of treatment is 5 - 10 days, depending on the severity of the disease.
Trial: NCT05472259
Drug: 5 FU
RxNorm normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
Trial: NCT05472259
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
Trial: NCT05122650
Drug: JZP385
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JZP385 capsules will be administered orally (PO) once daily in the morning on an empty stomach for 12 weeks.
Trial: NCT05275205
Drug: UBX1325 injection 50 μL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the UBX1325 arm will receive UBX1325 on Day 1, Weeks 4, 24, and 28
Trial: NCT05275205
Drug: EYLEA® (aflibercept) Injection 2 mg (0.05mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the active-control aflibercept arm will receive aflibercept per label every 8 weeks starting from day 1 until Week 40. In addition, these patients will receive UBX1325 on Week 24 and Week 32; and a sham procedure at Week 4 and Week 28.
Trial: NCT06433674
Drug: Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The pharmacy will be the one preparing the Zinc sulfate. The zinc sulfate comes in 220 mg tablets which are then mixed with 1 ml of Oral plus (a common suspending agent) as well as 9 ml of Sterile water. This then makes a Zinc Sulfate 22 mg/ml oral suspension which will be dispensed in an amber syringe.
Trial: NCT04272632
Drug: 4 ml/kg group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
Trial: NCT04272632
Drug: 8 ml/kg group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
Trial: NCT04272632
Drug: 12 ml/kg group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given immediately after spinal anesthesia.
Trial: NCT05194839
Drug: RIST4721
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RIST4721 tablets, 100 mg are blue, oval, biconvex film-coated tablets
Trial: NCT05194839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT05255094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered placebo by subcutaneous injection every 2 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Trial: NCT05255094
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered placebo by subcutaneous injection every 4 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Trial: NCT06048146
Drug: Experimental: FOLFOXIRI and Lateral lymph node dissection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 150mg /m2, d1, oxaliplatin 85mg/m2, d1, 5-Fu, 2400mg/m2, pumped continuously for 46 hours and repeated for 14 days
Trial: NCT06048146
Drug: Preoperative long-term concurrent chemoradiotherapy and Lateral lymph node dissection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy was administered five days a week (pelvic 2 Gy/ time, GT50 Gy) for five weeks with capecitabine (1650mg/m2/ day, orally divided into two doses). Intensity modulated radiotherapy (IMRT) was used
Trial: NCT05014334
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clarithromy 500mg, twice daily for 14 days.
Trial: NCT06390501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous (s.c. - under the skin) injection
Trial: NCT04776525
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 mg/m2 over four hours day 1
Trial: NCT04876755
Drug: MBM-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBM-02 is an HIF-1 and HIF-2 inhibitor.
Trial: NCT05731258
Drug: Liposomal doxorubicin containing regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal doxorubicin hydrochloride (PLD) 30-40mg/m2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles.
Trial: NCT06587737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo, lacking active ingredient, once-daily
Trial: NCT05917288
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care will be administered
Trial: NCT04867252
Drug: Resveratrol (1000mg twice a day), Myoinositol 1000mg (Twice a day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 51 Patients with PCOS receiving Resveratrol and Myoinositol 1000mg and 1000mg BD daily respectively
Trial: NCT05423522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One administration of 3 mL per day (1.8 mg/day) by depositing 1.5 mL in the gingivo-jugal groove of each cheek with the graduated pipette.
Trial: NCT05695313
Drug: OnLife®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is administered for the duration of PACLITAXEL chemotherapy with the first administration performed 5 days before the first PACLITAXEL administration. The OnLife supplement will be continued for another 4 weeks after the last PACLITAXEL administration.~One tablet in the morning and one in the evening daily
Trial: NCT04840264
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200 mg/square metre, D1, D8, D15, repeat every 4 weeks.
Trial: NCT06179303
Drug: Therapeutic Estradiol
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04231084
Drug: Vasodilator testing (Inhaled Nitric Oxide)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
Trial: NCT04231084
Drug: Vasodilator testing (Inhaled Epoprostenol)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
Trial: NCT05326659
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, applied twice daily for 12 weeks after enrolment.
Trial: NCT05530447
Drug: Samelisant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT05649228
Drug: Placebo Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A small amount of cream about the size of a U.S. quarter will be applied to participant's forearm using gloved fingers with visible cream left on the surface for one hour.
Trial: NCT04715152
Drug: ACB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive ultrasound-guided (USG) ACB with bupivacaine and dexamethasone 30 minutes before spinal anesthesia and sham intra-articular normal saline
Trial: NCT05566743
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: maintenance capecitabine after 4 months of FOLFRINOX
Trial: NCT06558656
Drug: NTQ5082 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1:The subjects are orally administered NT5082 capsules on an empty stomach in the first cycle and after a meal in the second cycle.~Part 2:The subjects are orally administered NT5082 capsules after a meal in the first cycle and on an empty stomach in the second cycle.
Trial: NCT05222737
Drug: spirazole forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adminstration of spirazole forte with a dose 17 mg per kg
Trial: NCT04993664
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The second group will receive placebo. Blood samples from all patients will be drawn for laboratory measurements and genetics determination. Ultrasound measurement of endothelium-dependent dilatation of the brachial artery and beta stiffness of carotid arteries will be measured.
Trial: NCT04227314
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 30 mg twice daily during the initial 12 week double blind placebo controlled period,
Trial: NCT05746897
Drug: NM1F Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of NM1F as monotherapy and in combination with pembrolizumab (Keytruda®) in subjects with unresectable locally advanced, or metastatic solid tumors.~The study consists of two parts: NM1F monotherapy dose escalation (Phase 1a), NM1F dose escalation in combination with a fixed dose of pembrolizumab (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period.
Trial: NCT05539729
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo created by the IDS and encapsulated in red coating to match the Study Drug.
Trial: NCT06259721
Drug: Anti-PD1 antibody, nimotuzumab and capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab (200mg), tislelizumab (200mg) or others; Intravenous infusion, every 3 weeks .~Nimotuzumab:: In the first 6 cycles, 200 mg, intravenous infusion, every 1 week, and 400 mg is administered for the first time.~Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks~Maintenance phase:~Anti-PD1 monoclonal antibody: anti-PD-1 monoclonal antibody drugs, Intravenous infusion, every 3 weeks.~Nimotuzumab treatment: 400 mg, intravenous infusion, every 3 weeks. Capecitabine: 1000 mg/m2, orally twice daily on days 1-14, every 3 weeks；~The duration of treatment is 1 year or until intolerable toxic reactions occur, or disease progresses, or the patient withdraws consent, or the investigator determines that the patient needs to withdraw from treatment.
Trial: NCT05465434
Drug: Zinc Supplement
RxNorm normalized name: Zinc supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc sulphate 50 mg
Trial: NCT04811404
Drug: Ethyl Eicosapentaenoic Acid
RxNorm normalized name: Ethyl eicosapentaenoate
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment will be for six weeks
Trial: NCT00000966
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00000966
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05000463
Drug: Convtrol group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The medical treatment included optimal glycemic control, vitamin B complex, a lipoic acid, selective serotonin reuptake inhibitors, and pregabalin.
Trial: NCT05465460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet orally four times per day for 14 days
Trial: NCT06470880
Drug: Adaptive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A blood test that measures the amount of tumour DNA circulating in the patient's blood (known as ctDNA) will be conducted every two weeks to check if the cancer cells are still present, and if they are becoming active. The result of this test will allow doctors to monitor the activity of the tumour and judge when to pause and resume encorafenib and binimetinib treatment. This intermittent treatment is called 'adaptive therapy'.
Trial: NCT06470880
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encorafenib and binimetinib delivered to UK standard of care.
Trial: NCT04812067
Drug: TTHX1114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: engineered FGF-1
Trial: NCT05564819
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When the infants woke up after surgery and were transported back to the ward, they were randomly divided into two groups immediately. The intervention group was given oral acetaminophen, once every 6 hours, for a total of 4 times.
Trial: NCT05429788
Drug: placebo inhaled dry powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo inhaled powder administered before public speaking challenge